DEFJ, LLC
Known title: 10% OwnerCIK: 0002147448
Associated companies
Transaction History
| RNAZ | ▼ Sell | Other | 11,813,859 | — | 8/3/2026 | View on chart |
| RNAZ | ▼ Sell | Other | 2,020,582 | — | 8/3/2026 | View on chart |
| RNAZ | ▼ Sell | Other | 11,813,859 | — | 8/3/2026 | View on chart |
| RNAZ | ▼ Sell | Other | 2,020,582 | — | 8/3/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
TransCode Reports Phase 1a Data for TTX-MC138
TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.
TransCode Reports Phase 1a Data for TTX-MC138. TransCode Therapeutics released updated results from its Phase 1a trial of TTX-MC138. The company reported continued disease stabilization and extended treatment duration in patients with advanced solid tumors. These findings add to the clinical evidence for the drug in heavily pretreated patients.